Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Estrella Immunopharma, Inc. - Common Stock
(NQ:
ESLA
)
1.750
+0.050 (+2.94%)
Streaming Delayed Price
Updated: 3:42 PM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
67,890
Open
1.720
Bid (Size)
1.700 (500)
Ask (Size)
1.760 (200)
Prev. Close
1.700
Today's Range
1.610 - 1.770
52wk Range
0.7800 - 3.150
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Which stocks are moving on Monday?
↗
April 06, 2026
Via
Chartmill
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
March 23, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Performance
YTD
+25.9%
+25.9%
1 Month
+49.6%
+49.6%
3 Month
+84.2%
+84.2%
6 Month
+4.2%
+4.2%
1 Year
+100.0%
+100.0%
More News
Read More
Monday's pre-market session: top gainers and losers
↗
February 09, 2026
Via
Chartmill
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 09, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Curious about the stocks that are showing activity after the closing bell on Friday?
↗
February 06, 2026
Via
Chartmill
Here are the top movers in Thursday's session.
↗
February 05, 2026
Via
Chartmill
Thursday's session: top gainers and losers
↗
February 05, 2026
Via
Chartmill
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
February 03, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
BioMedNewsBreaks – Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) Closes $8.0 Million Registered Direct Offering
January 07, 2026
Via
Investor Brand Network
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
January 06, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
January 05, 2026
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
December 04, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Tuesday's session: top gainers and losers
↗
November 04, 2025
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 04, 2025
Via
Benzinga
Which stocks are moving on Monday?
↗
November 03, 2025
Via
Chartmill
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
November 03, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
October 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 14, 2025
Via
Benzinga
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
October 06, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
June 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 03, 2025
Via
Benzinga
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
June 03, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
May 29, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
March 05, 2025
From
Estrella Immunopharma, Inc.
Via
Business Wire
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
↗
February 23, 2025
Via
Stocktwits
Frequently Asked Questions
Is Estrella Immunopharma, Inc. - Common Stock publicly traded?
Yes, Estrella Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Estrella Immunopharma, Inc. - Common Stock trade on?
Estrella Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Estrella Immunopharma, Inc. - Common Stock?
The ticker symbol for Estrella Immunopharma, Inc. - Common Stock is ESLA on the Nasdaq Stock Market
What is the current price of Estrella Immunopharma, Inc. - Common Stock?
The current price of Estrella Immunopharma, Inc. - Common Stock is 1.750
When was Estrella Immunopharma, Inc. - Common Stock last traded?
The last trade of Estrella Immunopharma, Inc. - Common Stock was at 04/15/26 03:42 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
